{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:27:00Z","timestamp":1777879620287,"version":"3.51.4"},"reference-count":21,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T00:00:00Z","timestamp":1329350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Psychopharmacology"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:p>Today, considering their adverse side effects, the first-generation antipsychotics have been replaced by the new-generation antipsychotics (also known as second-generation antipsychotic agents). The superiority of new-generation antipsychotics compared with first-generation antipsychotic agents in terms of side effects, especially movement disorders, are acknowledged by clinicians. But in recent years during the use of second-generation antipsychotic agents, endocrine side effects have been noteworthy. In our study with a diagnosis of paranoid schizophrenia treated with risperidone for 14 years and operated with the diagnosis of pituitary macroadenoma, a 32-year-old female patient is presented in the light of the literature examining the framework of the history of disease.<\/jats:p>","DOI":"10.1177\/2045125311433581","type":"journal-article","created":{"date-parts":[[2012,2,16]],"date-time":"2012-02-16T22:48:52Z","timestamp":1329432532000},"page":"85-89","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":6,"title":["Risperidone-induced acromegaly: a case report"],"prefix":"10.1177","volume":"2","author":[{"given":"Ay\u015fe","family":"Koroglu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cicek","family":"Hocaoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2012,2,16]]},"reference":[{"key":"bibr1-2045125311433581","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1472-8206.2009.00751.x","volume":"24","author":"Blanc O.","year":"2010","journal-title":"Fundamental Clin Pharmacol"},{"key":"bibr2-2045125311433581","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2010.04.008"},{"key":"bibr3-2045125311433581","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e32833ab099"},{"key":"bibr4-2045125311433581","first-page":"289","volume":"29","author":"Erer S.","year":"2008","journal-title":"Dialogues Clin Neurosci"},{"key":"bibr5-2045125311433581","doi-asserted-by":"crossref","unstructured":"Gianfrancesco F.D., Pandina G., Mahmoud R., Wu J., Wang R. (2009) Potential bias in testing for hyperprolactinemia and pituitary tumors in risperidone-treated patients: a claims-based study. 11: 5\u20138.","DOI":"10.1186\/1744-859X-8-5"},{"key":"bibr6-2045125311433581","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(02)00112-9"},{"key":"bibr7-2045125311433581","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2003-031199"},{"key":"bibr8-2045125311433581","doi-asserted-by":"publisher","DOI":"10.31887\/DCNS.2010.12.3\/jkane"},{"key":"bibr9-2045125311433581","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-1381"},{"key":"bibr10-2045125311433581","doi-asserted-by":"publisher","DOI":"10.4088\/JCP.v63n0506"},{"key":"bibr11-2045125311433581","first-page":"34","volume":"19","author":"Komossa K.","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"bibr12-2045125311433581","first-page":"44","volume":"9","author":"Kurt E.","year":"2008","journal-title":"Anatolian J Psychiatry"},{"key":"bibr13-2045125311433581","doi-asserted-by":"publisher","DOI":"10.3171\/2010.7.FOCUS10169"},{"key":"bibr14-2045125311433581","doi-asserted-by":"publisher","DOI":"10.1172\/JCI39375"},{"key":"bibr15-2045125311433581","doi-asserted-by":"publisher","DOI":"10.1530\/eje.1.02036"},{"key":"bibr16-2045125311433581","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2008.02.004"},{"key":"bibr17-2045125311433581","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200519001-00001"},{"key":"bibr18-2045125311433581","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e32833de61c"},{"key":"bibr19-2045125311433581","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0b013e32833abcba"},{"key":"bibr20-2045125311433581","doi-asserted-by":"publisher","DOI":"10.1592\/phco.26.6.748"},{"key":"bibr21-2045125311433581","first-page":"330","volume":"37","author":"Tajima K.","year":"2009","journal-title":"Actas Esp Psiquiatr"}],"container-title":["Therapeutic Advances in Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2045125311433581","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/2045125311433581","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/2045125311433581","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:49:02Z","timestamp":1777592942000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/2045125311433581"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,16]]},"references-count":21,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1177\/2045125311433581"],"URL":"https:\/\/doi.org\/10.1177\/2045125311433581","relation":{},"ISSN":["2045-1253","2045-1261"],"issn-type":[{"value":"2045-1253","type":"print"},{"value":"2045-1261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,16]]}}}